Neuroendocrine neoplasm of lung Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 24, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Neuroendocrine neoplasm of lung. It connects disease context, epidemiology, target mechanism, clinical competition, transactions, unmet need and market attractiveness for portfolio and partnering decisions.

Executive assessment

Neuroendocrine neoplasm of lung receives a directional strategic score of 64/100, combining unmet need (76/100), competitive intensity (78/100, where higher means more competition) and market attractiveness (79/100). The score is a transparent prioritization aid, not a revenue forecast, clinical recommendation or investment conclusion.

Disease background and strategic definition

A neoplasm with neuroendocrine differentiation that arises from the lung. This category includes typical carcinoid tumor, atypical carcinoid tumor, small cell carcinoma, large cell neuroendocrine carcinoma, and combined carcinoma.

The reproducible entity is Patsnap disease ID 863f609690954f78ab2e9d54013597ee. Stable identifiers are important because rare and precision-defined diseases often carry historical labels, gene-defined subtypes and overlapping syndromic names.

A credible target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, treatment setting, acceptable safety and endpoint. A broad label may inflate theoretical market size while weakening biological signal, trial interpretability and recruitment feasibility. The first population should be narrow enough for coherent biology but large enough for execution.

The care pathway should be mapped from symptom recognition through referral, diagnostic testing, treatment initiation and longitudinal monitoring. Diagnostic delay, limited specialist centers and fragmented testing can constrain both trial enrollment and commercial access. These bottlenecks deserve explicit operational assumptions.

Epidemiology and disease burden

Epidemiology evidence 1: Risk of Lung Cancer and Occupational Exposure to Polycyclic Aromatic Hydrocarbons Among Workers Cohorts — Worldwide, 1969–2022 Risk of Lung Cancer and Occupational Exposure to PolycyclicAromatic Hydrocarbons Among Workers Cohorts— Worldwide, 1969–2022

REFERENCES Bade BC, Cruz CSD. Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med 2020;41(1):1 − 24. http://dx.doi.org.sutd.idm.oclc.org/10. 1016/j.ccm.2019.10.001. 1. Mao YS, Yang D, He J, Krasna MJ. Epidemiology of lung cancer. Surg 2.

Review the epidemiology source

Epidemiology evidence 2: 江苏省启东市1972—2021年肺癌发病趋势及年龄-时期-队列模型分析 Incidence trend and age-period-cohort analysis of lung cancer in Qidong from 1972 to 2021

0.001), respectively. Age-specific incidence rates increased with age, peaking at 275.34/10 5 in the 75+ years age group, with an increasing trend in all age groups and the greatest increase in the 75+ years age group, with an AAPC value of 3.53% (P＜0.001). The results of the APC model showed that the net drift value of lung cancer incidence was 2.06% (95% CI: 1.72%-2.41%), and the highest value of local drift was 3.93% (95% CI: 3.20%-4.68%) in the 80+ years old group. The risk of cancer increases with age in the age effect. The period effect of the incidence rate ratio (RR) value increased from 1.12 during 1997-2001 to 2.09 during 2017-2021. The cohort effect of the RR value for risk of incidence increased from 0.17 during 1892-1896 to 2.54 during 1987-1991. Conclusions From 1972 to 2021, the incidence rate of lung cancer in Qidong City showed an upward trend. Age, period, and cohort are all major factors influencing the incidence of lung cancer. It is necessary to develop precise and comprehensive prevention and control strategies to curb this increasing trend of lung cancer incidence. 【Key words】 Lung neoplasms; Incidence rate; Epidemic trends; Age-period-cohort model; Qidong Fund programs: Nantong University Special Research Fund for Clinical Medicine (2024JY050); Project of Invigorating Health Care through Science, Technology, and Education of Nantong's "14th Five-year Plan" (2021-15); Nantong Municipal Health Committee Scientific Research Project (MS2023121)

Review the epidemiology source

Epidemiology evidence 3: Global, Regional, and National Burden of Tracheal, Bronchus, and Lung Cancer in 2022: Evidence from the GLOBOCAN Study Global, Regional, and National Burden of Tracheal, Bronchus,and Lung Cancer in 2022: Evidence from the GLOBOCAN Study

### Chart Data Transcription Report 1. Basic Chart Information * Chart Title: Table 1. Burden of Tracheal, Bronchus, and Lung cancer in 2022, by sex. * Chart Type: Comparative Data Table * Contextual Summary: This table presents the global and regional burden of Tracheal, Bronchus, and Lung (TBL) cancers in 2022, detailing incidence, deaths, and mortality-to-incidence ratios, stratified by sex for various geographical regions. 2. Chart Structure and Elements * Axes/Headers: * Row Headers: Geographical regions/labels (Australia-New Zealand, Caribbean, Central America, Eastern Africa, Eastern Asia, Eastern Europe, Melanesia, Micronesia, Middle Africa, Northern Africa, Northern America, Northern Europe, Polynesia, South America, South Central Asia, South-Eastern Asia, Southern Africa, Southern Europe, Western Africa, Western Asia, Western Europe, Global). * Column Headers: * Incidence: * Count: Both, Males, Females * Age-Standardized Rate: Both, Males, Females * Deaths: * Count: Both, Males, Females * Age-Standardized Rate: Both, Males, Females * Mortality to Incidence Ratio: Both, Males, Females * Legend/Groups: Not applicable. * Notes and Footnotes: Data source: GLOBOCAN 2022. 3. Detailed Data Transcription This table presents the incidence, deaths, and mortality-to-incidence ratios for Tracheal, Bronchus, and Lung cancer in 2022, stratified by sex, across various regions and globally. * Australia-New Zealand: * Incidence Count: Both: 16,222; Males: 9012; Females: 7210 * Incidence Age-Standardized Rate: Both: 24.6; Males: 28; Females: 21.6 * Deaths Count: Both: 11,313; Males

Review the epidemiology source

Translate epidemiology into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence cannot be substituted for one another, and incompatible case definitions should not be pooled.

For Neuroendocrine neoplasm of lung, quantify diagnostic yield, age and severity distribution, referral-center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges. Each parameter should have a source, access date and explanation of how it maps to the intended clinical population.

Population concentration can materially change strategy. A small but well-defined group managed in a limited number of centers may be operationally attractive, while a larger but poorly diagnosed population may require extensive testing and education. Epidemiology must therefore connect to the real patient journey.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: irreversible progression, incomplete control, treatment-limiting toxicity, weak durability, burdensome administration, delayed diagnosis or lack of options for a biomarker-defined subgroup. Disease severity alone does not prove that a new program can demonstrate clinically meaningful benefit.

A strong Neuroendocrine neoplasm of lung thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Functional measures, patient-reported outcomes and resource use may complement biomarkers.

Development should proceed through evidence gates. Establish phenotype and natural history, demonstrate target engagement, observe a pharmacodynamic response, show an interpretable clinical signal and only then scale toward registrational development. Pre-agreed stop criteria protect capital and improve learning from negative results.

Target mechanism anchor: PTH1R

G protein-coupled receptor for parathyroid hormone (PTH) and for parathyroid hormone-related peptide (PTHLH) (PubMed:10913300, PubMed:18375760, PubMed:19674967, PubMed:27160269, PubMed:30975883, PubMed:35932760, PubMed:8397094). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (cAMP) (PubMed:30975883, PubMed:35932760). PTH1R is coupled to G(s) G alpha proteins and mediates activation of adenylate cyclase activity (PubMed:20172855, PubMed:30975883, PubMed:35932760). PTHLH dissociates from PTH1R more rapidly than PTH; as consequence, the cAMP response induced by PTHLH decays faster than the response induced by PTH (PubMed:35932760).

The mechanism anchor is PTH1R. It is a pathway hypothesis, not a claim that every Neuroendocrine neoplasm of lung patient is target-dependent. Translational work should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and a therapeutic window.

Critical experiments include orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit on-target and off-target safety testing. Human evidence should carry greater weight than model-only observations. Related clinical failures should be examined for exposure, population and endpoint lessons.

A go decision requires a complete chain: relevant target biology, achievable modulation at tolerated exposure, measurable pharmacodynamic change and a plausible bridge to clinical benefit. Missing links should trigger targeted experiments rather than narrative confidence.

Clinical development and competitive landscape

The focused query returned 51 registered studies. Recent sampled records include:

• NCT07357623 — Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors; Recruiting; Phase 2; sponsor Shanghai Chest Hospital; enrollment 96.
• ChiCTR2600116780 — Phase Ⅱ Clinical Study of Surufatinib Combined with Temozolomide as First-line Therapy for Pulmonary Neuroendocrine Tumors; Pending; Phase 2; sponsor Fu Jian Yi Ke Da Xue Fu Shu Di Er Yi Yuan; enrollment 27.
• ChiCTR2500113228 — A Single-arm, Multi-center, Open-label Phase II Study to Investigate the Efficacy and Safety of Serplulimab in Combination with Chemotherapy in First-line Treatment of Pulmonary Neuroendocrine Carcinoma; Recruiting; Phase 2; sponsor 302 Military Hospital of China; enrollment 14.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies from one asset can inflate activity. Normalize every record by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy should compare against the likely future standard at launch. Whitespace can arise from earlier treatment, genotype selection, improved durability, lower monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim must be visible in protocol design, not deferred to post hoc interpretation.

Recruitment risk is a core strategic variable. Site density, diagnostic testing, travel burden, competing protocols and screen-failure rates should inform country and center selection. Natural-history work can reduce uncertainty but cannot replace a controlled efficacy strategy when outcomes are variable.

Transaction activity and partnering attractiveness

The search returned 1 recent directly matched transaction records:

• Phanes Therapeutics, Inc. Announces Clinical Supply Agreement with Roche to Evaluate PT217 in Combination with an anti-PD-L1 Therapy (2024-05-08). Review stage, rights, territory, milestones and disclosed economics before using it as a comparable.

Headline transaction value is rarely directly comparable. Separate upfront payments, milestones, royalties, options, bundled programs, platform rights and geographic scope. A useful comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual property, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that retires material risk.

Low direct deal activity can represent whitespace, but it can also signal difficult science or economics. Broader therapeutic-area transactions should be used only when their relevance is explicit. Avoid assuming that all rare-disease transactions share the same valuation logic.

Market attractiveness and access

Market attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, alternatives, monitoring burden and geographic reimbursement. Patient count is only one driver. Reliable identification and a meaningful effect may outweigh a small population; fragmented diagnosis can undermine a larger one.

The commercial model should use scenario ranges for diagnosed prevalence, eligible share, launch timing, competitive entries, net price, persistence and penetration. Every assumption should be traceable. Refresh the model when new epidemiology, trial or deal evidence becomes available.

Payer research should begin before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Evidence may need quality of life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The value proposition should connect clinical effect to stakeholder-relevant outcomes.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate PTH1R relevance in the selected phenotype.
• Translation risk: connect engagement to a biomarker and meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing and screen-failure assumptions.
• Commercial risk: test pricing, access and adoption with clinicians and payers.
• Data risk: treat zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are population confirmation, human mechanism validation, differentiated target product profile, early proof of mechanism and scale-up only after biological, clinical, operational and commercial signals converge.

Strategic recommendation

Neuroendocrine neoplasm of lung merits continued milestone-based evaluation. The opportunity is strongest if a phenotype or biomarker identifies patients with coherent biology, if PTH1R modulation is measurable and if the proposed benefit remains differentiated against future care. Current evidence supports targeted diligence rather than unconditional investment.

The near-term business-development objective is a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard offers a common comparison language while preserving evidence gaps and uncertainty.

Methodology and source note

This report was assembled on August 24, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update.

Ranking weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio commitment.

Conclusion

The key question for Neuroendocrine neoplasm of lung is whether a biologically grounded therapy can deliver material patient benefit in an identifiable population and remain differentiated through launch. The evidence assembled here supplies a structured starting point, while the explicit gaps define the next diligence plan.